BioCryst Pharmaceuticals | BCRX - Equity Capital And Reserves


BioCryst Pharmaceuticals reported $-553.84M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
Chugai Pharma JPY 2.03T 135.62B Dec/2025
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
DBV Technologies USD 168.77M 115.92M Dec/2025
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Glaxosmithkline GBP 22.06B 360M Dec/2025
Incyte USD 5.62B 455.37M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Novavax USD -144.76M 17.01M Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026